Zhang, Hai-Ying, Liu, Zhan-Dong, Hu, Chao-Jun et al. · Journal of the Formosan Medical Association = Taiwan yi zhi · 2011 · DOI
Researchers measured levels of a immune signaling molecule called TGF-β1 in blood cells from ME/CFS patients and compared them to healthy people and patients with other illnesses. They found that ME/CFS patients had significantly higher levels of TGF-β1 than both groups, suggesting this molecule may play a role in ME/CFS disease development.
This study provides molecular evidence for immune dysregulation in ME/CFS, specifically implicating TGF-β1 as a potentially measurable biomarker. Understanding aberrant immune signaling in ME/CFS could eventually lead to diagnostic tests and targeted therapeutic interventions.
This study does not prove that TGF-β1 elevation causes ME/CFS—it only shows an association. The cross-sectional design prevents determination of whether TGF-β1 elevation precedes disease onset, is a consequence of illness, or both. The study also does not establish what clinical significance this elevation has or whether it correlates with symptom severity.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →